摘要
目的 寻找难治性小儿丙型肝炎的有效治疗方法。方法 采用基因工程α干扰素联合利巴韦林 (病毒唑 ,维克拉 ,Ribavirin)治疗 15例经α干扰素治疗无效或复发、病程长者达 5～ 9年的难治性小儿丙型肝炎。采用年龄分组的方法 ,经病毒血清及肝脏组织病理学检查确诊。结果 本组平均年龄 6～ 8岁 ,最大 10岁 ,最小 6个月 ,平均病程 4 5年 ,男 12例 ,女 3例 ,14例有输注血制品史。经联合治疗后 ,血清HCVRNA阴转率为 12 / 15 ,平均阴转时间为 3个月 ,最短 1 5个月 ,最长为 5个月。本组无一例出现严重不良反应。一过性发热和感冒样症状与单独应用α干扰素无差别。个别 (2例 )病例有一性轻度纳差 ,恶心 ,部分病例 (9例 )有一过性血色素轻度下降 ,降幅平均值为 5 g/L ,最多者降幅为 2 0g/L ,网织红细胞均有一过性轻度升高。均不影响治疗 ,可自行恢复。未见皮疹 ,白细胞和血小板减少及肾功异常改变。结论 α干扰素联合利巴韦林治疗难治性小儿丙型肝炎是有效、安全、可靠的 。
Objective To explore more efficacious therapy for chronic hepatitis C in children. Methods With combination of recombinant interferon α/ribavirin therapy, we treated 15 children, with viral sera and biopsy proven chronic hepatitis C, who did not respond to the treatment of interferon α alone and had frequently relapse, with the disease courses of 5 9 years (mean 4.5 years). Mean age of the children (12 males and 3 females) was 6.8 years (6 months 10 years). 14 patients had blood transfusion history. Results HCV RNA in 12 patients was negative after combined treatment of 3 months (1.5 5 months). None of the patients treated had skin rash and severe adverse reaction. Transient fever and influenza like symptoms with combined therapy were similar to those with interferon α therapy alone. Hemoglobin level decreased slightly in 9 patients (mean decrease by 5 g/L; max, 20 g/L). Reticulocytes elevated slightly. White blood cells, platelets, Bun and Cr were normal in all the patients. Conclusion Our results show that combination of interferon α with ribavirin for treatment of hepatitis C in children is efficacious, safe and reliable. It deserves popularization.
出处
《中华实验和临床病毒学杂志》
CAS
CSCD
北大核心
2001年第1期81-82,共2页
Chinese Journal of Experimental and Clinical Virology
